Blood Biomarkers as Prognostic Indicators for Neurological Injury in COVID-19 Patients: A Systematic Review and Meta-Analysis
Open Access
- 30 October 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (21) , 15738
Abstract
Coronavirus disease 2019 (COVID-19) has been linked to various neurological complications. This meta-analysis assessed the relationship between glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in the blood and neurological injury in COVID-19 patients. A comprehensive search of various databases was conducted until 18 August 2023, to find studies reporting GFAP and NfL blood levels in COVID-19 patients with neurological complications. GFAP and NfL levels were estimated between COVID-19 patients and healthy controls, and meta-analyses were performed using RevMan 5.4 software for analysis. In the 21 collected studies, it was found that COVID-19 patients had significantly higher levels of pooled GFAP (SMD = 0.52; 95% CI: 0.31, 0.73; p ≤ 0.001) and NfL (SMD = 0.60; 95% CI: 0.37, 0.82; p ≤ 0.001) when compared to the healthy controls. The pooled GFAP (SMD = 0.86; 95% CI: 0.26, 1.45; p ≤ 0.01) and NfL (SMD = 0.87; 95% CI: 0.48, 1.26; p ≤ 0.001) were significantly higher in non-survivors. These findings indicate a significant association between COVID-19 severity and elevated levels of GFAP and NfL, suggesting that GFAP and NfL could serve as potential diagnostic and prognostic markers for the early detection and monitoring of COVID-19-related neurological injuries.Keywords
Funding Information
- Health and Medical Research Fund Commissioned Research on COVID-19 (COVID1903007, RiFood, 1-CD55)
- internal funding for Research Institute (COVID1903007, RiFood, 1-CD55)
This publication has 68 references indexed in Scilit:
- Insights into neurological dysfunction of critically ill COVID-19 patientsTrends in Anaesthesia and Critical Care, 2021
- Quantification of Neurological Blood-Based Biomarkers in Critically Ill Patients With Coronavirus Disease 2019Critical Care Explorations, 2020
- Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19Neurology, 2020
- Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19Journal of Neurology, 2020
- Plasma biomarkers of astrocytic and neuronal dysfunction in early‐ and late‐onset Alzheimer's diseaseAlzheimer's & Dementia, 2020
- Neurofilament light chain in the assessment of patients with multiple sclerosisArquivos de Neuro-Psiquiatria, 2019
- Neurofilament light chain as a biomarker in neurological disordersJournal of Neurology, Neurosurgery & Psychiatry, 2019
- Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort studyCritical Care, 2015
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile rangeBMC Medical Research Methodology, 2014
- Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological DiseasesPLOS ONE, 2013